Genes may predict toxicity to leukaemia therapy:
This article was originally published in Clinica
Executive Summary
US researchers have identified genetic variations - polymorphisms - that could cause children with acute lymphoblastic leukaemia (ALL) to react badly to some chemotherapy drugs. The findings could help patients avoid harmful and potentially life-threatening side-effects of these drugs, and potentially allow doctors to individualise ALL chemotherapy according to each patient. "Such individualised therapy would eliminate the time-consuming trial-and-error approach to finding the right dose for a patient," said researcher Mary Relling, of St Jude's Children's Research Hospital in Memphis, Tennessee. The researchers identified 16 polymorphisms within genes that are known to affect the influence the pharmacodynamics of the drug in the body. The findings are published in the May 15 issue of Blood.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.